8-K: Summit Therapeutics Presents Updated HARMONi Trial Data

Summit Therapeutics announced updated overall survival results from its global Phase III HARMONi clinical trial, demonstrating consistent efficacy with ivonescimab plus chemotherapy.

Summary

• Updated overall survival (OS) results from the global Phase III HARMONi clinical trial for ivonescimab plus chemotherapy were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer (WCLC 2026).
• The HARMONi trial evaluated ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC) after prior third-generation EGFR TKI treatment.
• An updated analysis with a June 2026 data cut-off showed a statistically significant OS hazard ratio of 0.76 (nominal p=0.0151) in the global intention-to-treat (ITT) population, with median OS of 16.8 months versus 14.0 months.
• Western patients in the HARMONi trial demonstrated consistent OS improvement with longer follow-up (median 23.2 months), mirroring results seen in Asian patients.
• No new safety signals were observed with ivonescimab plus chemotherapy in the updated HARMONi data.
• Data from the Akeso-sponsored HARMONi-2 Phase III trial in China was also presented, showing ivonescimab monotherapy achieved a statistically significant OS benefit compared to pembrolizumab monotherapy (HR 0.73, p=0.009).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with updated data reinforcing the efficacy of ivonescimab and aligning with the upcoming BLA decision date.

Positives

• Updated overall survival data from the global Phase III HARMONi trial shows a statistically significant OS benefit (HR 0.76, p=0.0151) with ivonescimab plus chemotherapy.
• Consistent OS improvement was observed in western patients with longer follow-up, reinforcing regional consistency of efficacy.
• The safety profile of ivonescimab plus chemotherapy remains acceptable and manageable, with no new safety signals identified.
• Data from the HARMONi-2 trial in China demonstrated a statistically significant OS benefit for ivonescimab monotherapy versus pembrolizumab monotherapy (HR 0.73, p=0.009).
• Summit's Biologics License Application (BLA) for ivonescimab has a PDUFA goal action date of November 14, 2026.

Negatives

• The primary OS analysis in April 2025 showed a positive trend but did not achieve statistical significance (HR 0.79, p=0.057) with median OS of 16.8 months vs. 14.0 months.
• While western patients showed a consistent OS improvement in the June 2026 analysis (HR 0.76, 95% CI: 0.52-1.10), the confidence interval includes 1.0, indicating some uncertainty.
• Serious treatment-related adverse events (TRAEs) were higher in the HARMONi-2 study for ivonescimab (29.9%) compared to pembrolizumab (21.6%).

Risks

• The BLA submission is based on the HARMONi trial, and the FDA's final decision is pending.
• The confidence interval for the western subgroup OS hazard ratio in the HARMONi trial (0.52-1.10) includes 1.0, suggesting potential variability.
• Global public health crises could affect the timing and status of clinical trials and operations.
• The company's ability to sell shares under its At-The-Market equity offering program and prevailing capital market conditions could impact funding.
• The outcome of discussions with regulatory authorities, including the FDA, remains a key factor.

Future Outlook

Summit's Biologics License Application (BLA) with the FDA has a PDUFA goal action date of November 14, 2026. The company is working towards potential approval of ivonescimab based on the HARMONi trial results.

Management Comments

• "Updated results from the global Phase III HARMONi study show that ivonescimab combined with chemotherapy continued to demonstrate a consistent overall survival improvement compared with placebo plus chemotherapy in patients with EGFR-mutated non-small cell lung cancer following prior treatment with a third-generation EGFR TKI."
• "Importantly, with longer follow-up, the survival improvement observed in western patients was consistent with the global population, reinforcing the relevance of these results across geographic regions in a setting where patients continue to need additional treatment options after progression on EGFR-targeted therapy."
• "The updated HARMONi overall survival analysis presented at WCLC 2026 provides important additional evidence of the consistency of ivonescimabs clinical profile across patient populations, with western patients showing consistent survival improvement to what was observed in Asian patients."
• "Together with the continued acceptable and manageable safety profile, these data reinforce our confidence in the HARMONi results as we work toward the potential approval of ivonescimab in the U.S."
• "What continues to distinguish ivonescimab is not only the strength of these HARMONi results, but the expanding clinical data sets emerging across studies and tumor types, including recent positive results from HARMONi-2 and HARMONi-GI1 in biliary tract cancer."
• "Together, these data reinforce our belief in the potential breadth of ivonescimabs differentiated bispecific design as an important new therapeutic approach in oncology, beginning with EGFR-mutated non-small cell lung cancer and extending across our broader ambition to address serious needs in solid tumors where patients urgently need better options."

Industry Context

StockSavvy.ai notes that the presentation of updated survival data at a major oncology conference like WCLC 2026 is a standard practice for biopharmaceutical companies seeking to bolster their regulatory submissions and commercial positioning. The focus on overall survival, particularly with longer follow-up, is critical for demonstrating long-term patient benefit in lung cancer, a highly competitive therapeutic area.

Comparison to Industry Standards

• In the HARMONi trial, the median OS of 16.8 months for ivonescimab plus chemotherapy in the ITT population (vs. 14.0 months for placebo) is a notable improvement, though the initial primary analysis did not reach statistical significance.
• The OS hazard ratio of 0.76 (nominal p=0.0151) in the updated HARMONi analysis is competitive with other second-line NSCLC therapies, but direct comparisons are complex due to differing patient populations and trial designs.
• In the HARMONi-2 trial, the OS hazard ratio of 0.73 (p=0.009) for ivonescimab monotherapy versus pembrolizumab monotherapy suggests a potential advantage over a standard-of-care immunotherapy in a specific patient subgroup (China market). Pembrolizumab monotherapy is a widely used standard in first-line NSCLC for PD-L1 high patients, and in second-line settings.
• The safety profile of ivonescimab appears manageable, with serious TRAEs at 29.9% in HARMONi-2, which is comparable to or slightly higher than some immunotherapy combinations, but lower than certain chemotherapy regimens.

Stakeholder Impact

• Shareholders: Positive impact expected from updated efficacy data supporting potential regulatory approval and future commercialization of ivonescimab.
• Patients: Potential for a new treatment option for EGFR-mutated NSCLC patients who have progressed on prior therapy.
• Healthcare Providers: Presentation of data at WCLC 2026 provides clinicians with updated information on ivonescimab's efficacy and safety profile.

Next Steps

• Await the FDA's decision on the Biologics License Application (BLA) for ivonescimab, with a PDUFA goal action date of November 14, 2026.
• Continue to present clinical data at scientific conferences to support the development and potential commercialization of ivonescimab.
• Expand clinical development into other tumor types and indications as planned (e.g., HARMONi-GU1 in urothelial carcinoma).

Key Dates

Recommendation

The updated data is positive and reinforces confidence in ivonescimab's efficacy, particularly with the statistically significant OS benefit in the latest HARMONi analysis and the HARMONi-2 results. However, the BLA decision date is November 14, 2026, and the western subgroup confidence interval in HARMONi still includes 1.0. Therefore, a 'hold' recommendation is prudent pending the FDA's final decision, while acknowledging the encouraging clinical data.

Keywords

ivonescimab, non-small cell lung cancer, NSCLC, EGFR-mutated, clinical trial, overall survival, chemotherapy, biopharmaceutical